Michael is a research associate in our Drug Discovery Program. He first joined the Nathanson Lab as an undergraduate researcher in 2021 and has since graduated from UCLA ('24) with a Molecular, Cell, and Developmental Biology BS and Biomedical Research minor. Currently, he is helping to develop next-generation potent and brain-penetrant tyrosine kinase inhibitors for glioblastoma (GBM). Specifically, he investigates DMPK/PD aspects of these novel inhibitors including brain penetrance and drug exposure, in vivo efficacy, protein reactivity, and dose tolerability. He is applying to medical schools in 2025.